UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Masquerading as Type 2 DM:
• LADALatent Autoimmune Diabetes of Adults
• T3c DM“other types” or pancreatogenic diabetes
Mary E. Steward, APRN-CNP, MS, MPH, CDEAssistant Professor, Internal MedicineOU School of Community Medicine, Tulsa, OK
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Speaker Disclosure
• I have no financial relationships or affiliations to disclose.
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Making the Diagnosis“IDDM” = obsolete term
• Age at presentation– 50% of T1DM may be
diagnosed >30 yrs.
• Body Habitus– 50% T1DM w/BMI >25– 25% T1DM +2 signs
Metabolic syndrome
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Types of Diabetes
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
LADA• “Type 1.5”• Autoimmune DM progressing slowly
– May not need insulin for 6 mos-6 yrs.• 4-14% of people dx with DM
– 15-20% of people dx with T2DM• Do not initially require insulin at dx.• Share genetic features with T1 & T2• Family Hx is common, esp T1DM• BMI <35 typical, age 25-40 common
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
LADA Labs• C-peptide (.8-3.1)
– low to normal in early disease– Low to undetectable, late– If high, use insulin sensitizer
• Autoantibodies: **GAD,** Islet cell, IA2 (islet tyrosine phosphatase 2/insulinoma assoc antigen), Insulin Autoantibody, Zn co-transporter A, freq positive for only 1.
• TIP: Check C-peptide first, if <1, get GAD
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
LADA vs T2DM
• Better Metabolic profile: – Lower BMI– lower blood pressure– better lipids– fewer signs Metabolic Syndrome
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
LADA vs T1DM
• Less aggressive Beta cell loss– May tolerate delayed insulin start
(not advised)
• Fewer multiple auto-antibodies– Higher GAD antibody titer =
• faster progression • more severe beta cell loss• quicker progression to insulin
• Risk for DKA is lower, increases with length of dx.
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Management of LADA
• Insulin primary, similar to T1DM, physiologic regimen, for islet cell preservation
– Augments beta-islet function– Reduces hyperglycemia– Decreases severity of insulitis– Suppresses auto reactive T-cells
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA Postprandial Pattern “stairstep”
Fasting Pattern “wave”
GLUCOSE PATTERNS
HIGHBaseline
HIGHExcursions from AM, Lability
Normal1-2 hrs.excursions
B L S
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Management of LADA cont.
Potential to preserve beta cell function• DPP4 inhibitors may improve beta cell
function, GLP-1 incretins• Metformin if insulin resistance or TZD
Avoid sulfonylureas—deplete endogenous reserve
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Screen for Autoimmune
• Increased risk other autoimmune– Esp. thyroid– More common
LADA>T2DM
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
CV Risk
• Risk is lower than DM2 generallymonitor BPuse statinsexercisediet weight management
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Don’t be Fooled!
• Lower BMI <35• Age at onset 20-50• Less Family Hx DM• Less response to Lifestyle• Marked postprandial pattern• Insulin required within 3 yrs of
diagnosis?
–Think LADA
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
65 yrs. CM BMI 26, wt 200# Dx DM2 2002
• Actos/glipizide/Januvia/Lantus 40units HSmetformin intolerance
• Neg FH DM• PMH: Htn, Chol., A. fib, Barrett’s• TSH wnl. • A1c 8.5%, despite careful food choices• +Periph neurop on foot exam
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Labs
• C-peptide 0.37 (.8-3.1)
• GAD 5.3+ (<5) - autoantibodies can diminish in longstanding disease
• Negative ICA <1:4, IA2 <0.8
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
LADA
• Stop orals for DM2• Lower basal significantly (20 units)• Start low dose meal insulin
– insulin:carb ratio of 1:15 or 1:20• Many LADA may have had dramatic
response to meal analog insulin in past with hypo & reluctant to restart, be conservative
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
33 yrs. CF, Dx DM2 2014BMI 27, Wt 178
• Metformin 1000 BID, Levemir 25 BID, Novolog 5 TID Premeal
• PMH: anxiety, substance abuse-cannabis, amphetamines, panic disorder, PTSD
• A1c 12.2% MPG 360• Office BS 135 fasting
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Lab
• C-peptide 0.62 (.8-3.1)
• Likely insulin omission & liquid carbs contributed to high A1c
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Lab/Dx• GAD 8 (<5)
LADA• Stop metformin • Zero calorie drinks• Rebalance insulin basal/bolus (@.6/kg = 50 units)
• Switch to once daily basal (Lantus, Basaglar, Tresiba, Toujeo)
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Masquerading as DM2 –T3c
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
T3cDM Distribution
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
T3c• >75% from chronic pancreatitis• 1-9% prevalence of DM patients, average of 4-
5% most populations• Typically >age 50• Deficient insulin production, reduced islet # & function
• Impaired pancreatic function– Inhibited glucose-stimulated insulin release
from pro-inflammatory cytokines– Hepatic & peripheral insulin resistance– Reduced incretin effect
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Pathophysiology – Incretins (5)
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Alcohol-associated Chronic Pancreatitis
• Cumulative presence of DM– 50 % at 10 yrs.– 83% at 25 yrs.
• Exocrine insufficiency usually pre-dates endocrine insufficiency
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Chronic Pancreatitis (CP)
• 50% endocrine insufficiency (75% T3c)
• 80% exocrine deficiency– Within 5 yrs. of diagnosis
• Repeated acute attacks cause cumulative tissue damage, collagen deposition, scar formation that blocks glandular structure & function
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Exocrine Dysfunction CP• Malabsorption
– Weight loss, muscle depletion– Diarrhea– Steatorrhea
• Digestive Enzyme replacement with meals
• Reduction of fat intake• Small, multiple meals throughout day• Fat soluble Vit D monitoring• High risk atraumatic fracture
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Additional Challenges CP
• Epigastric pain & use of opioids– ?pancreatic neuropathy, responsive to
TCA, gabapentin, pregabalin, SSRI• Alcohol & smoking cessation –
metabolic/exogenous toxins• T3c “pancreatogenic” diabetes more
likely w/surg. resection esp. distal pancreas, smoking, longer duration CP dx, pancreatic calcifications
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Labs T3c
• Normal to low C-peptide based on disease progression
• Negative Auto-antibodies• Normal insulin sensitivity• Low risk DKA early, higher as disease
progresses• Low serum levels lipid soluble
Vitamins D, E, K• Labile glucose swings
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Treatment T3c DM• A1c <8% - metformin (GI side
effects), reduces risk of pancreatic Ca (antineoplastic properties)
• Decreased hepatic insulin sensitivity, unsuppressed hepatic glucose output– Reduced pancreatic polypeptide
secretion alpha cells causing erratic glucose swings
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Treatment T3c DM cont.
• Insulin as next therapy• Caution risk hypo (SU, insulin),
loss of counterregulatory hormones, impaired nutrient absorption, low glycogen stores, exaggerated peripheral sensitivity to insulin, persistent alcohol intake, poor dietary intake due to pain, smoking, alcohol, postprandial symptom avoidance
• AVOID: Incretin-based therapies like GLP-1, DPP4 inhibitors; TZDs
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Treatment T3c DM cont.• Regular meal pattern with standardized
CHO intake, do not skip meals
• Small, frequent meals, rich in soluble fiber, low in fat, Vit D supplement
• Avoid alcohol & smoking• Enzyme replacement, stabilize postprandial BS/incretin
• Minimize high sugar food & fluids• Monitor glucose, test if symptoms of low
• Avoid sugar alcohols (sorbitol) laxative effect
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
PMH
• Past or current pancreatic disease?• Alcohol history?
12 oz
1 oz
5 oz
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Microvascular Complications
• May be at greater risk– Regular dilated eye exam– Urine microalbumin– Neuropathy evaluations– Foot checks
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Risk/Complications
• Risk for pancreatic cancer– CP is 5% over 20 yrs.– DM2 over 2x standard population risk– T3cDM may be a “harbinger”
• Macrovascular complications less common
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
43 yrs. HISP M. BMI 33, wt. 246 #
• PMH: hypothyroid, elev BP w/o dx Htn, pancreatitis, alcohol abuse, venous stasis
• FH: neg DM• Labs: A1c 10.4% MPG 293, office BS
164• Dx: DM2 Started on metformin ER
500mg, 2 tab BID.
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Lab
• C-peptide 0.5 (.8-3.1)
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Lab/Dx
• GAD Autoantibody <5 (<5)
DM T3c• Start insulin (A1c 10.4%), wt 246#,
Simple regimen to start Novolog Mix 70/30, 24 units BID, before largest 2 meals
• Continue metformin 2g/day (eGFR >45)
for antineoplastic & IR benefits
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
37 yrs HISP M, Dx DM2 2005,BMI 44, wt. 350#
• Novolog 20 TID premeal, Lantus 35 BIDmetformin intolerant
• FH + DM2• Periph neurop, Bilat retinop, Necrobiosis
lipoidica, hx. DM foot ulcer, venous insufficiency
• 3/2018 Leukocytoclastic vasculitis• 12/2018 Acute pancreatitis/necrosis,
NAFLD, CT w/cirrhosis
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Lab
• Labs: A1c 11.8% MPG 314• Meds: Creon, methadone,
gabapentin . . .
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Dx DM2
• Pre-existing DM2• Complication of pancreatitis
• Further eval. liquid carbs, insulin omission, injection site hypertrophy, incidence hypoglycemia/how treated
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Don’t be Fooled!
• Pancreatitis/GI history– Weight loss, muscle depletion– Diarrhea– Steatorrhea– Epigastric pain, esp postprandial
• Age ~50• Alcohol & smoking history
–Think T3c
UN
IVER
SITY
OF
OKL
AHO
MA,
TU
LSA
Masquerading as Type 2 DM:
• LADALatent Autoimmune Diabetes of Adults
• T3c DM“other types” or pancreatogenic diabetes
Mary E. Steward, APRN-CNP, MS, MPH, CDEAssistant Professor, Internal MedicineOU School of Community Medicine, Tulsa, OK